Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Finished Goods (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Finished Goods for 5 consecutive years, with $14.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Finished Goods rose 80.97% to $14.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $14.5 million, a 80.97% increase, with the full-year FY2024 number at $10.7 million, up 270.12% from a year prior.
  • Finished Goods was $14.5 million for Q3 2025 at Rhythm Pharmaceuticals, up from $13.6 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $14.5 million in Q3 2025 to a low of $111000.0 in Q4 2021.
  • A 5-year average of $5.7 million and a median of $2.9 million in 2023 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: soared 75.68% in 2022, then soared 1384.62% in 2023.
  • Rhythm Pharmaceuticals' Finished Goods stood at $111000.0 in 2021, then skyrocketed by 75.68% to $195000.0 in 2022, then skyrocketed by 1384.62% to $2.9 million in 2023, then soared by 270.12% to $10.7 million in 2024, then surged by 35.71% to $14.5 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Finished Goods are $14.5 million (Q3 2025), $13.6 million (Q2 2025), and $12.6 million (Q1 2025).